100%
Draft Survey - Collaboration Mode
General Comments
Enabled peer-review/collaboration.
- grassroots  6 years ago, 28-Sep-2017
 
Questions marked with an * are required Exit Survey
 
 Add Comments (0)  Edit
 
Dear Readers,

We invite you to participate in our annual "Year's Best in Hematology" poll from The Hematologist --- a review of the past year’s top clinical and scientific breakthroughs in hematology. The editorial board has compiled a list of 15 breakthroughs, and we ask that you rate the influential nature of each on a scale of 1 (most influential) to 5 (least influential), and choose “Not sure” for the selections you decide not to rank. The poll takes approximately 1-2 minutes to complete!

Results will be included alongside the editors’ choices in the January/February 2017 issue of The Hematologist. The poll will be open through December 22, 2016.

Thank you for your vote!
Jason Gotlib
Editor-in-Chief, The Hematologist
 
 
 Add Comments (0)  Edit
Please rate the following on a scale from 1 (most influential) to 5 (least influential)
#1 - Highly influential #2 #3 #4 #5 - Least influential Not sure
* Checkpoint inhibition and other immunotherapy approaches in lymphomas
* The treatment revolution in hemophilia
* Application of CRISPR Cas9 genome editing in hematologic disease
* Mechanistic basis for CALR-mutated MPNs
* Novel insights into mitochondrial regulation of hematopoiesis
* BTK inhibition in the frontline treatment of chronic lymphocytic leukemia
* The precision medicine initiative in acute myeloid leukemia
* Daratumumab: changing the treatment landscape of myeloma
* Reduction of the cost and hospital burden of heparin-induced thrombocytopenia
* Immunotherapy advances in pediatric and adult acute lymphoblastic leukemia
* Andexanet alfa for acute major bleeding associated with Factor Xa inhibitors
* Multikinase/KIT inhibitor midostaurin in advanced systemic mastocytosis
* No effect on mortality of short-term versus long-term storage of blood
* Platelet transfusions are inferior to standard care after acute stroke due to intracerebral hemorrhage
* Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anemia (the TWiTCH trial)
 
 Add Comments (0)  Edit
 
Option #1
   
 
 Add Comments (0)  Edit
 
Option #2
   
 
 Add Comments (0)  Edit
 
Option #3